Clinical trials
Relapsed or Refractory Multiple Myeloma clinical trials
Below are recruiting relapsed or refractory multiple myeloma clinical trials, each written for real people, not researchers. We’re tracking 1,289 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05204459Recruiting
MRI and eye-scan study for MS and related conditions
This trial uses brain MRI and eye imaging tests to study research markers in people with multiple sclerosis (MS) and related neurologic conditions. It may help researchers better understand these diseases and how they change over time.
Los Angeles, CaliforniaAges 18 years+ - NCT05272384RecruitingPhase 1
Testing nivolumab plus ASTX727 for hard-to-treat lymphoma
This Phase 1 study tests whether adding ASTX727 to nivolumab can shrink relapsed or refractory B-cell lymphomas that have come back or did not respond to treatment. It also aims to find a safe dosing plan and see early signs of benefit in certain lymphoma types.
Birmingham, AlabamaAges 18 years+ - NCT05964829Recruiting
Test a leg sleeve to improve walking in multiple sclerosis
This trial studies whether using the Cionic “Neural Sleeve” can improve walking and leg movement in people with multiple sclerosis (MS). It may help if your MS affects mobility, and you can safely wear and tolerate the device during the day.
Cleveland, OhioAges 22–75 - NCT06138132RecruitingPhase 1
CAR-T cell therapy for progressive multiple sclerosis
This trial is testing a type of immunotherapy called CAR-T cells (made from your own immune cells) to see if it can help slow or stop progressive multiple sclerosis. It is a very early safety study, so only people with progressive MS who meet strict health criteria can join.
Palo Alto, CaliforniaAges 18–65 - NCT06276634Recruiting
Low-Oxygen Therapy for People With Multiple Sclerosis
This study tests whether brief, controlled low-oxygen episodes (called intermittent hypoxia) can improve motor function in people with MS. It may help strengthen walking and daily movement.
Chicago, IllinoisAges 18–75 - NCT06453044RecruitingPhase 2
Study of two drugs for follicular lymphoma that came back
This study tests a combination of two targeted drugs (mosunetuzumab and polatuzumab vedotin) for people with follicular lymphoma that has come back or not responded to previous treatment. The goal is to see if this two-drug approach can help shrink tumors and control the disease.
Duarte, CaliforniaAges 18 years+ - NCT06483048RecruitingPhase 1
MUC1-targeted T cells for relapsed ovarian cancer
This trial tests a new treatment using your own immune cells, modified to target a protein called MUC1 on ovarian cancer cells. It is for people with ovarian cancer that has come back or is resistant to standard treatments.
Scottsdale, ArizonaAges 18 years+ - NCT07042438RecruitingPhase 2
Fecal transplant to improve CAR T therapy for lymphoma
This study tests whether a fecal transplant (transferring healthy gut bacteria) can improve outcomes for people with certain lymphomas who have taken strong antibiotics and are about to get CAR T-cell therapy (Yescarta). The goal is to see if rebuilding gut bacteria helps the treatment work better.
Duarte, CaliforniaAges 18 years+ - NCT07193823Recruiting
Sexual function study for women with MS
This study looks at sexual health in women with relapsing-remitting multiple sclerosis. It aims to understand how MS might affect sexual function and to find ways to help.
Izmir, BornovaAges 25–50 - NCT05706220Enrolling by invitation
Eye tests to measure visual speed in multiple sclerosis
This study tests how fast and how accurately your eyes process visual information and how eye movements look in people with multiple sclerosis. It may help researchers understand vision-related effects of MS using objective eye measurements.
Valladolid, ValladolidAges 18–80 - NCT06672705RecruitingPhase 1
Epcoritamab for post-transplant lymphoma that didn't respond to treatment
This trial tests a new drug called epcoritamab for people whose PTLD (a type of lymphoma that can happen after an organ transplant) has come back or hasn't been helped by standard treatments. The goal is to see if epcoritamab can shrink or control the cancer.
St Louis, MissouriAges 18 years+ - NCT07532525RecruitingPhase 1
Pomalidomide after CAR T for B-cell cancer
This trial tests whether the drug pomalidomide, given as a pill, can help people with B-cell leukemia or lymphoma who have recently received CAR T-cell therapy. The goal is to see if pomalidomide can keep the cancer from coming back, and it may be an option for those whose cancer is not growing but still needs management.
Ann Arbor, MichiganAges 18 years+ - NCT03418038RecruitingPhase 2
Vitamin C with chemotherapy for certain relapsed blood cancers
This Phase 2 trial tests whether intravenous vitamin C (ascorbic acid) added to chemotherapy can improve outcomes for people with certain relapsed or treatment-resistant lymphomas or chronic myelomonocytic leukemia (CMML). It may help by boosting chemotherapy’s effectiveness and/or changing how the cancer responds.
Mankato, MinnesotaAges 18 years+ - NCT03896269RecruitingPhase 1
CPX-351 for high-risk MDS or CMML that came back
This Phase 1 trial studies CPX-351, a cancer medicine, in people with high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) whose disease relapsed or did not respond to prior treatment. It may help shrink or control the leukemia and improve blood counts in patients who cannot or do not want a stem cell transplant.
Houston, TexasAges 18 years+ - NCT04047641RecruitingPhase 1/Phase 2
Quizartinib with chemotherapy for new or returning leukemia
This trial tests a combination of anti-leukemia drugs (including quizartinib) together with chemotherapy for people with acute myeloid leukemia (AML), a rare mixed-type leukemia, or high-risk myelodysplastic syndrome (MDS). It may help by trying to better control cancer in people whose disease is newly diagnosed or has returned/not responded to prior treatment.
Houston, TexasAges 18 years+ - NCT04604041Recruiting
Study early warning signs in relapsing-remitting multiple sclerosis
This study looks at “subclinical markers,” meaning early or hidden body changes that may show how relapsing-remitting multiple sclerosis (MS) is doing even when symptoms seem mild. It may help researchers find better ways to monitor MS and detect changes sooner.
SplitAges 18–65 - NCT04848064RecruitingPhase 1
Natural killer cells plus mogamulizumab for skin lymphoma
This early-phase study tests a combination of “natural killer” immune cells and a medicine called mogamulizumab to treat certain skin lymphomas that have come back or did not respond. It may help your immune system better find and attack cancer cells.
Columbus, OhioAges 18 years+ - NCT05292664RecruitingPhase 1
Venetoclax trial for high-risk blood cancers in young patients
This Phase 1 study tests venetoclax to treat certain high-risk blood cancers in children, teens, or young adults. It is designed to see if the drug can work safely for patients whose disease has returned or did not respond to prior treatment.
San Francisco, CaliforniaAges 1–40 - NCT05751044RecruitingPhase 1/Phase 2
Study of four medicines for children with difficult blood cancers
This Phase 1/2 trial tests a combination of medicines (dasatinib, venetoclax, dexamethasone, cyclophosphamide, and cytarabine) in children and teens whose blood cancer has come back or did not respond to treatment. It aims to see whether this approach can control the cancer while checking what doses are safe.
ViennaAges 1–21 - NCT06390930Recruiting
Breathing bursts of lower oxygen for hand function in MS
This study tests whether breathing short bursts of reduced oxygen (acute intermittent hypoxia) can improve hand function and nerve health in people with relapsing-remitting MS who have some hand weakness.
Chicago, IllinoisAges 18–75 - NCT03874052RecruitingPhase 1
Ruxolitinib plus venetoclax and azacitidine for relapsed AML
This early-phase study tests a combination of ruxolitinib with venetoclax, with or without azacitidine, for adults whose acute myeloid leukemia (AML) has come back or does not respond to treatment. It may help by stopping cancer cells from growing and improving blood counts, with the exact plan guided by the study arm you’re assigned to.
Columbus, OhioAges 18 years+ - NCT06854159RecruitingPhase 2
Odronextamab for diffuse large B-cell lymphoma before and after CAR T therapy
This trial tests a drug called odronextamab for people with diffuse large B-cell lymphoma that has come back or not responded to at least two prior treatments. It aims to see if the drug can help before and after a type of immunotherapy called CAR T-cell therapy.
Sacramento, CaliforniaAges 18 years+ - NCT07061951RecruitingPhase 2
Mirdametinib for relapsed or refractory CLL or SLL
This trial tests a drug called mirdametinib for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to at least two prior treatments, including a BTK inhibitor and a BCL2 inhibitor. The goal is to see if mirdametinib can help shrink the cancer or slow its growth.
Duarte, CaliforniaAges 18 years+ - NCT07072247RecruitingPhase 1
RN1201 injection for hard-to-treat antibody-mediated blood disorders
This trial tests a new injection called RN1201 for people with antibody-mediated diseases, specifically two types of blood disorders: platelet transfusion refractoriness (PTR) and immune thrombocytopenia (ITP) that haven't responded to standard treatments. The goal is to see if RN1201 can help control these conditions.
Suzhou, JiangsuAges 16–65
Hear when a new Relapsed or Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory multiple myeloma?
- Yes. Clin2 currently lists 1,289 recruiting relapsed or refractory multiple myeloma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory multiple myeloma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.